Richard W. Keatinge

Bausch Health Americas, Inc. manufactures and distributes pharmaceutical products. The company was founded on November 29, 2011 and is headquartered in Bridgewater, NJ.

Digital Gene Technologies, Inc. develops technology designed to enable researchers to measure gene expression levels in various disease models. The company is headquartered in La Jolla, CA.

Cytheris SA develops and manufactures drugs for immune modulation. It is a clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases. The firm's product CYT107 (glycosylated r-hIL-7), is in clinical development for two targeted indications with urgent medical needs and no current treatments: Progressive Multifocal Leukoencephalopathy (PML) in severely lymphopenic patients and Reduction of complications in Immune Non-Responders with HIV controlled by anti-retroviral treatment (HIV-INR). Cytheris has locations in France and The United States. The company was founded in January 1999 by Michel Morre and is headquartered in Issy-les-Moulineaux, France.

FeRx Inc. develops, manufactures, and distributes magnetic targeted carrier technology for the treatment of cancer. Its technology is used in therapeutic areas and provides technology platform for delivery of small molecules, radionuclides, biologics and genetic vectors. The company was registered in 1997 and is headquartered in San Diego, CA.